GlassScriptPhysician profile
Diana V Huckaby
NPI 1902355977
$22,938.26
in general payments reported to CMS, 2019-2025
58 companies · $4,660 in 2025
The $4,660 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,299 · 2022: $4,708 · 2023: $4,418 · 2024: $4,853 · 2025: $4,660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,931.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,427.96 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $2,254.21 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $1,313.49 | 2021-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,255.74 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Abbott Laboratories | $1,243.39 | 2021-2025 | Freestyle Libre 3 |
| Mannkind Corporation | $1,151.38 | 2021-2025 | Afrezza |
| Ascensia Diabetes Care US INC. | $1,062.77 | 2023-2025 | |
| Amgen INC. | $1,041.38 | 2021-2025 | Evenity, Repatha, Prolia |
| Radius Health, INC. | $908.49 | 2021-2025 | Tymlos |
| Novartis Pharmaceuticals Corporation | $764.68 | 2021-2025 | |
| Corcept Therapeutics | $710.83 | 2021-2025 | Korlym |
| Dexcom, INC. | $709.86 | 2021-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $707.87 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Recordati_rare_diseases_inc. | $650.87 | 2021-2025 | Isturisa, Signifor Lar |
| Cequr Corporation | $601.26 | 2022-2025 | Cequr Simplicity |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $581.39 | 2021-2025 | Minimed 780g, Intellis Adaptivestim, Inpen Smart Insulin Delivery System |
| Abbvie INC. | $547.48 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $455.23 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $387.92 | 2021-2025 | |
| Kyowa Kirin, INC. | $357.77 | 2023-2025 | Crysvita |
| Zealand Pharma US, INC. | $355.54 | 2021-2022 | |
| Esperion Therapeutics, INC. | $319.87 | 2021-2025 | Nexletol |
| Amarin Pharma, INC. | $312.54 | 2021-2023 | |
| Sequel Med Tech, LLC | $269.26 | 2025 | Twiist |
| Antares Pharma, INC. | $258.28 | 2021-2023 | Tlando, Nocdurna, Xyosted |
| Ultragenyx Pharmaceutical INC. | $235.25 | 2021-2022 | |
| Insulet Corporation | $204.16 | 2021-2025 | Omnipod |
| Madrigal Pharmaceuticals | $163.01 | 2025 | Rezdiffra |
| Neurocrine Biosciences, INC. | $162.36 | 2023-2025 | Ongentys, Ingrezza |
| Mirum Pharmaceuticals, INC. | $147.27 | 2024 | Livmarli |
| Alexion Pharmaceuticals, INC. | $144.43 | 2021-2025 | Strensiq |
| Eusa Pharma (US) LLC | $109.74 | 2022 | |
| Soleno Therapeutics, INC. | $109.10 | 2025 | Vykat Xr |
| Ipsen Biopharmaceuticals, INC | $100.61 | 2021-2022 | |
| Becton, Dickinson and Company | $95.72 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $84.77 | 2022 | |
| Lifescan, INC. | $68.80 | 2021-2023 | |
| Acerus Pharmaceuticals Corporation | $63.16 | 2021-2022 | |
| Tandem Diabetes Care, INC. | $62.62 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Rhythm Pharmaceuticals, INC. | $59.99 | 2025 | Imcivree |
| Averitas Pharma INC. | $58.12 | 2023-2025 | Qutenza |
| Grt US Holding, INC. | $37.52 | 2022 | |
| Nestle Healthcare Nutrition INC. | $32.90 | 2021 | |
| Clarus Therapeutics INC. | $32.82 | 2021 | |
| Vivus LLC | $30.64 | 2021 | |
| Pfizer INC. | $28.18 | 2024-2025 | |
| Tolmar, INC. | $27.46 | 2023 | |
| Currax Pharmaceuticals LLC | $26.82 | 2021-2022 | |
| Beta Bionics, INC. | $26.15 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Ionis Pharmaceuticals, INC. | $23.31 | 2025 | Tryngolza |
| Bigfoot Biomedical INC | $22.42 | 2022 | |
| Almatica Pharma LLC | $21.96 | 2024 | Teriparatide |
| Halozyme INC | $21.18 | 2023 | |
| Glaxosmithkline, LLC. | $20.84 | 2025 | Arexvy, Shingrix |
| Amryt Pharma Holdings LTD | $18.54 | 2021 | |
| Rgh Enterprises LLC | $18.53 | 2025 | |
| Nevro Corp. | $16.48 | 2021 | |
| Amphastar Pharmaceuticals, INC. | $13.94 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Huckaby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.